ZELTIQ Aesthetics (ZELTIQ Aesthetics) Long-Term Capital Lease Obligation : $0.0 Mil (As of Dec. 2016)

View and export this data going back to 2011. Start your Free Trial

What is ZELTIQ Aesthetics Long-Term Capital Lease Obligation?

ZELTIQ Aesthetics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2016 was $0.0 Mil.

ZELTIQ Aesthetics's quarterly Long-Term Capital Lease Obligation declined from Jun. 2016 ($0.1 Mil) to Sep. 2016 ($0.0 Mil) but then stayed the same from Sep. 2016 ($0.0 Mil) to Dec. 2016 ($0.0 Mil).

ZELTIQ Aesthetics's annual Long-Term Capital Lease Obligation declined from Dec. 2014 ($0.3 Mil) to Dec. 2015 ($0.1 Mil) and declined from Dec. 2015 ($0.1 Mil) to Dec. 2016 ($0.0 Mil).

ZELTIQ Aesthetics Long-Term Capital Lease Obligation Historical Data

The historical data trend for ZELTIQ Aesthetics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZELTIQ Aesthetics Long-Term Capital Lease Obligation Chart

ZELTIQ Aesthetics Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.26

0.14

ZELTIQ Aesthetics Quarterly Data
	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.14	0.11	0.07	-	-

ZELTIQ Aesthetics (NAS:ZLTQ) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

ZELTIQ Aesthetics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of ZELTIQ Aesthetics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ZELTIQ Aesthetics Inc (NAS:ZLTQ) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.coolsculpting.com

ZELTIQ Aesthetics Inc was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, it changed its name to ZELTIQ Aesthetics, Inc. ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled cooling technology platform. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.

Executives

Todd Erik Zavodnick	officer: President, International	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Bradley Hauser	officer: SVP, Research and Development	C/O ZELTIQ AESTHETICS, INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Danika R Harrison	officer: SVP of Global Marketing	C/O ZELTIQ AESTHETICS, INC. 4410 ROSEWOOD DRIVE PLEASANTON CA 94588
Mark J Foley	director, officer: President and CEO	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Taylor C. Harris	officer: SVP & Chief Financial Officer	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Kevin C Oboyle	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher	director	C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
D Keith Grossman	director
Andrew N Schiff	director, 10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Keith J Sullivan	officer: CCO, President, North America	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Patrick F. Williams	officer: SVP & CFO	C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Leonard C Debenedictis	officer: Chief Technical Officer	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Bryan E Roberts	director	C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Jean George	director	CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Aisling Capital Iii Lp	10 percent owner	888 Seventh Avenue, 30th Fl, New York NY 10106

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Headlines

No Headlines